Mild Cognitive Impairment Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major mild cognitive impairment markets are expected to exhibit a CAGR of 4.02% during 2024-2034.
The mild cognitive impairment market has been comprehensively analyzed in IMARC's new report titled "Mild Cognitive Impairment Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mild cognitive impairment refers to a condition characterized by noticeable cognitive changes that are greater than expected for an individual's age and education level but do not significantly interfere with daily functioning. Some of the common symptoms are memory difficulties like forgetfulness of recent events or important information, challenges with attention and concentration, problems with language, including word-finding difficulties or trouble expressing thoughts, etc. Additionally, individuals suffering from the ailment may experience a reduced ability to make decisions or solve problems and mild impairments in visuospatial skills, such as getting lost in familiar surroundings. Diagnosing mild cognitive impairment involves a comprehensive evaluation that includes a medical history assessment, cognitive testing, and clinical examination. Healthcare professionals, such as neurologists, use standardized cognitive assessments to evaluate various cognitive domains, including memory, attention, language, executive functions, etc. In addition to this, they may consider the input of the patient and their close contacts to assess changes in cognitive abilities and daily functioning. Numerous imaging tests, such as magnetic resonance imaging (MRI), may be conducted to rule out other underlying causes or conditions.
The increasing cases of neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease, which result in the progressive degeneration of neurons in specific areas of the brain, are primarily driving the mild cognitive impairment market. In addition to this, the rising prevalence of various associated risk factors, such as mental health disorders like depression and anxiety, certain vascular diseases that affect blood flow to the brain, lack of mental and social stimulation, advancing age, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of novel medications, including cholinesterase inhibitors and memantine, which enhance neurotransmitter activity and help to manage memory and thinking problems, is further bolstering the market growth. Apart from this, the inflating application of cognitive rehabilitation programs that involve structured interventions, such as memory training, attention exercises, problem-solving tasks, etc., for improving specific cognitive abilities is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-invasive brain stimulation techniques, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), since they facilitate synaptic changes and enhance neural plasticity, thereby leading to improved cognitive function, is expected to drive the mild cognitive impairment market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the mild cognitive impairment market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mild cognitive impairment and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mild cognitive impairment market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mild cognitive impairment market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mild cognitive impairment market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mild cognitive impairment marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the mild cognitive impairment market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mild cognitive impairment market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mild cognitive impairment market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mild cognitive impairment across the seven major markets?
What is the number of prevalent cases (2018-2034) of mild cognitive impairment by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mild cognitive impairment by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mild cognitive impairment across the seven major markets?
What is the size of the mild cognitive impairment patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mild cognitive impairment?
What will be the growth rate of patients across the seven major markets?
Mild Cognitive Impairment: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mild cognitive impairment drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mild cognitive impairment market?
What are the key regulatory events related to the mild cognitive impairment market?
What is the structure of clinical trial landscape by status related to the mild cognitive impairment market?
What is the structure of clinical trial landscape by phase related to the mild cognitive impairment market?
What is the structure of clinical trial landscape by route of administration related to the mild cognitive impairment market?
The mild cognitive impairment market has been comprehensively analyzed in IMARC's new report titled "Mild Cognitive Impairment Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mild cognitive impairment refers to a condition characterized by noticeable cognitive changes that are greater than expected for an individual's age and education level but do not significantly interfere with daily functioning. Some of the common symptoms are memory difficulties like forgetfulness of recent events or important information, challenges with attention and concentration, problems with language, including word-finding difficulties or trouble expressing thoughts, etc. Additionally, individuals suffering from the ailment may experience a reduced ability to make decisions or solve problems and mild impairments in visuospatial skills, such as getting lost in familiar surroundings. Diagnosing mild cognitive impairment involves a comprehensive evaluation that includes a medical history assessment, cognitive testing, and clinical examination. Healthcare professionals, such as neurologists, use standardized cognitive assessments to evaluate various cognitive domains, including memory, attention, language, executive functions, etc. In addition to this, they may consider the input of the patient and their close contacts to assess changes in cognitive abilities and daily functioning. Numerous imaging tests, such as magnetic resonance imaging (MRI), may be conducted to rule out other underlying causes or conditions.
The increasing cases of neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease, which result in the progressive degeneration of neurons in specific areas of the brain, are primarily driving the mild cognitive impairment market. In addition to this, the rising prevalence of various associated risk factors, such as mental health disorders like depression and anxiety, certain vascular diseases that affect blood flow to the brain, lack of mental and social stimulation, advancing age, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of novel medications, including cholinesterase inhibitors and memantine, which enhance neurotransmitter activity and help to manage memory and thinking problems, is further bolstering the market growth. Apart from this, the inflating application of cognitive rehabilitation programs that involve structured interventions, such as memory training, attention exercises, problem-solving tasks, etc., for improving specific cognitive abilities is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-invasive brain stimulation techniques, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), since they facilitate synaptic changes and enhance neural plasticity, thereby leading to improved cognitive function, is expected to drive the mild cognitive impairment market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the mild cognitive impairment market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mild cognitive impairment and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mild cognitive impairment market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mild cognitive impairment market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mild cognitive impairment market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mild cognitive impairment marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the mild cognitive impairment market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mild cognitive impairment market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mild cognitive impairment market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mild cognitive impairment across the seven major markets?
What is the number of prevalent cases (2018-2034) of mild cognitive impairment by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mild cognitive impairment by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mild cognitive impairment across the seven major markets?
What is the size of the mild cognitive impairment patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mild cognitive impairment?
What will be the growth rate of patients across the seven major markets?
Mild Cognitive Impairment: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mild cognitive impairment drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mild cognitive impairment market?
What are the key regulatory events related to the mild cognitive impairment market?
What is the structure of clinical trial landscape by status related to the mild cognitive impairment market?
What is the structure of clinical trial landscape by phase related to the mild cognitive impairment market?
What is the structure of clinical trial landscape by route of administration related to the mild cognitive impairment market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MILD COGNITIVE IMPAIRMENT - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MILD COGNITIVE IMPAIRMENT - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MILD COGNITIVE IMPAIRMENT - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MILD COGNITIVE IMPAIRMENT - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MILD COGNITIVE IMPAIRMENT - UNMET NEEDS
10 MILD COGNITIVE IMPAIRMENT - KEY ENDPOINTS OF TREATMENT
11 MILD COGNITIVE IMPAIRMENT - MARKETED PRODUCTS
11.1 List of Mild Cognitive Impairment Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MILD COGNITIVE IMPAIRMENT - PIPELINE DRUGS
12.1 List of Mild Cognitive Impairment Pipeline Drugs Across the Top 7 Markets
12.1.1 AGB 101 - AgeneBio
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SAGE718 - Sage Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MILD COGNITIVE IMPAIRMENT - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MILD COGNITIVE IMPAIRMENT – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MILD COGNITIVE IMPAIRMENT - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mild Cognitive Impairment - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mild Cognitive Impairment - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mild Cognitive Impairment - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mild Cognitive Impairment - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mild Cognitive Impairment - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mild Cognitive Impairment - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mild Cognitive Impairment - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mild Cognitive Impairment - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mild Cognitive Impairment - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mild Cognitive Impairment - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mild Cognitive Impairment - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mild Cognitive Impairment - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mild Cognitive Impairment - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mild Cognitive Impairment - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mild Cognitive Impairment - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mild Cognitive Impairment - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mild Cognitive Impairment - Access and Reimbursement Overview
16 MILD COGNITIVE IMPAIRMENT - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MILD COGNITIVE IMPAIRMENT MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MILD COGNITIVE IMPAIRMENT MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MILD COGNITIVE IMPAIRMENT - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MILD COGNITIVE IMPAIRMENT - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MILD COGNITIVE IMPAIRMENT - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MILD COGNITIVE IMPAIRMENT - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MILD COGNITIVE IMPAIRMENT - UNMET NEEDS
10 MILD COGNITIVE IMPAIRMENT - KEY ENDPOINTS OF TREATMENT
11 MILD COGNITIVE IMPAIRMENT - MARKETED PRODUCTS
11.1 List of Mild Cognitive Impairment Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MILD COGNITIVE IMPAIRMENT - PIPELINE DRUGS
12.1 List of Mild Cognitive Impairment Pipeline Drugs Across the Top 7 Markets
12.1.1 AGB 101 - AgeneBio
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 SAGE718 - Sage Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MILD COGNITIVE IMPAIRMENT - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MILD COGNITIVE IMPAIRMENT – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MILD COGNITIVE IMPAIRMENT - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mild Cognitive Impairment - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mild Cognitive Impairment - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mild Cognitive Impairment - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mild Cognitive Impairment - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mild Cognitive Impairment - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mild Cognitive Impairment - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mild Cognitive Impairment - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mild Cognitive Impairment - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mild Cognitive Impairment - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mild Cognitive Impairment - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mild Cognitive Impairment - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mild Cognitive Impairment - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mild Cognitive Impairment - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mild Cognitive Impairment - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mild Cognitive Impairment - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mild Cognitive Impairment - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mild Cognitive Impairment - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mild Cognitive Impairment - Access and Reimbursement Overview
16 MILD COGNITIVE IMPAIRMENT - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MILD COGNITIVE IMPAIRMENT MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MILD COGNITIVE IMPAIRMENT MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
